2024
The association of reduced ejection fraction with the outcomes of endovascular abdominal aortic aneurysm repair
Bellamkonda K, Zogg C, Desai N, Strosberg D, Stone D, Guzman R, Ochoa Chaar C. The association of reduced ejection fraction with the outcomes of endovascular abdominal aortic aneurysm repair. Journal Of Vascular Surgery 2024, 81: 866-876. PMID: 39725244, DOI: 10.1016/j.jvs.2024.12.039.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Aneurysm, AbdominalBlood Vessel Prosthesis ImplantationCardiomyopathiesDatabases, FactualEndovascular ProceduresFemaleHumansMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesRisk AssessmentRisk FactorsStroke VolumeTime FactorsTreatment OutcomeUnited StatesVentricular Function, LeftConceptsEndovascular aneurysm repairEjection fractionReduced EFIschemic cardiomyopathyNormal EFNonischemic cardiomyopathyAneurysm repairOutcomes of endovascular abdominal aortic aneurysm repairOutcomes of endovascular aneurysm repairEndovascular abdominal aortic aneurysm repairAssociated with higher 30-day mortalitySymptomatic abdominal aortic aneurysmElective endovascular aneurysm repairAbdominal aortic aneurysm repairHigher 30-day mortalityVascular Quality Initiative databaseAssociated with high mortalityAortic aneurysm repairVascular Surgery guidelinesAbdominal aortic aneurysmLong-term mortalityVascular Quality InitiativeSeverity of cardiomyopathyReduction of EFSurgery guidelinesPrognostic significance of phase analysis using SPECT myocardial perfusion imaging in heart failure: a systematic review and meta-analysis
Lee K, Han S, Ryu J, Cho S, Moon D. Prognostic significance of phase analysis using SPECT myocardial perfusion imaging in heart failure: a systematic review and meta-analysis. The International Journal Of Cardiovascular Imaging 2024, 41: 27-35. PMID: 39535673, DOI: 10.1007/s10554-024-03278-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac-Gated Single-Photon Emission Computer-Assisted TomographyFemaleHeart FailureHumansMaleMiddle AgedMyocardial Perfusion ImagingPredictive Value of TestsPrognosisRisk AssessmentRisk FactorsTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftVentricular Function, LeftConceptsLeft ventricular mechanical dyssynchronyMyocardial perfusion SPECTHF patientsCardiac deathHeart failurePrognostic significancePrognostic valueGated SPECTPerfusion SPECTPooled HRMeta-analysisHazard ratioSPECT myocardial perfusion imagingAll-causeVentricular mechanical dyssynchronyAdverse cardiac eventsMyocardial perfusion imagingAdverse cardiovascular eventsPublication biasConfidence intervalsAnalysis of SPECTSystematic reviewRandom-effects modelMechanical dyssynchronyPrognostic factorsMetabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, Windsor S, Ilkayeva O, Muehlbauer M, Newgard C, Borlaug B, Kitzman D, Shah S, Margulies K, Husain M, Inzucchi S, McGuire D, Lanfear D, Javaheri A, Umpierrez G, Mentz R, Sharma K, Kosiborod M, Shah S. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circulation Heart Failure 2024, 17: e011980. PMID: 39421941, PMCID: PMC11634023, DOI: 10.1161/circheartfailure.124.011980.Peer-Reviewed Original ResearchMeSH KeywordsAgedBenzhydryl CompoundsBiomarkersClinical Trials, Phase IV as TopicFatty AcidsFemaleGlucosidesHeart FailureHumansMaleMetabolomicsMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsStroke VolumeTreatment OutcomeVentricular Function, LeftConceptsHeart failureBranched-chain amino acidsEnd pointsEjection fractionLeft ventricular ejection fraction spectrumMetabolite factorsMetabolic effectsSpectrum of ejection fractionSGLT2 inhibitor dapagliflozinReduced ejection fractionHF-related outcomesEjection fraction spectrumMechanisms of benefitDEFINE-HFAcid metabolismInhibitor dapagliflozinOverall cohortMetabolomic profilesLVEFMetabolic signaturesRandomized trialsDapagliflozinHF subtypesFatty acid metabolismAmino acid metabolismCardiomyopathy‐Associated Chronic Heart Failure in Infants Aged <1 Year: A Prospective Observational Cohort Over 5 Years in Northern China
Ding W, Wang B, Hong J, Lu L, Xiao Y, Shan G, Myers C, Yu Q, Spurney C, Li Z, Han L. Cardiomyopathy‐Associated Chronic Heart Failure in Infants Aged <1 Year: A Prospective Observational Cohort Over 5 Years in Northern China. Journal Of The American Heart Association 2024, 13: e029121. PMID: 39344650, PMCID: PMC11681489, DOI: 10.1161/jaha.122.029121.Peer-Reviewed Original ResearchConceptsBundle-branch blockHeart failureVentricular noncompactionReduced left ventricular ejection fractionInfants aged <1 yearPatients up to 5Infants aged <1Pediatric heart centersOutcomes of infantsPresence of left bundle-branch blockVentricular ejection fractionLeft ventricular noncompactionEjection fraction groupChronic heart failureProspective observational studyYear of diagnosisChinese pediatric populationSecondary to cardiomyopathyProspective observational cohortIncreased heart sizeFavorable predictorsBaseline LVEFEjection fractionNo significant differenceMedical therapyLong‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Shah A, Fox S, Wang A. Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study. Journal Of The American Heart Association 2024, 13: e030607. PMID: 38591260, PMCID: PMC11262496, DOI: 10.1161/jaha.123.030607.Peer-Reviewed Original ResearchMeSH KeywordsBenzylaminesCardiomyopathy, HypertrophicHumansPilot ProjectsStroke VolumeUracilVentricular Function, LeftConceptsObstructive hypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire–Overall Summary scoreSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientHypertrophic cardiomyopathyNew York Heart Association class improvementLeft ventricular outflow tract gradientTreatment-emergent adverse eventsSerum NT-proBNP levelsLeft ventricular ejection fractionEffect of mavacamtenIndividual dose titrationNT-proBNP levelsVentricular ejection fractionSerum NT-proBNPSummary scoreLong-term safetyLonger-term treatmentDose titrationEjection fractionNT-proBNPB-blockersReduced doseAdverse eventsInterim resultsDapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER
Peikert A, Vaduganathan M, Claggett B, Kulac I, Foà A, Desai A, Jhund P, Carberry J, Lam C, Kosiborod M, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Køber L, Ponikowski P, Sabatine M, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 912-924. PMID: 38487939, DOI: 10.1002/ejhf.3184.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionHeart failureHistory of MIMyocardial infarctionPrimary outcomeDAPA-HFWorsening HFSpectrum of left ventricular ejection fractionLeft ventricular ejection fraction spectrumCardiovascular deathSodium-glucose cotransporter 2 inhibitorsRisk of disease progressionComposite of cardiovascular deathRisk of adverse cardiovascular outcomesIncreased risk of adverse cardiovascular outcomesRisk of cardiovascular deathVentricular ejection fractionHistory of myocardial infarctionSerious adverse eventsAdverse cardiovascular outcomesSymptomatic HFEjection fractionAdverse eventsCovariate-adjusted modelsPooled analysisTorsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Kapelios C, Greene S, Mentz R, Ikeaba U, Wojdyla D, Anstrom K, Eisenstein E, Pitt B, Velazquez E, Fang J, Investigators T. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circulation Heart Failure 2024, 17: e011246. PMID: 38436075, PMCID: PMC10950535, DOI: 10.1161/circheartfailure.123.011246.Peer-Reviewed Original ResearchMeSH KeywordsCardiomyopathiesFemaleFurosemideHeart FailureHumansMalePatient DischargeStroke VolumeTorsemideTreatment OutcomeVentricular Function, LeftConceptsLeft ventricular ejection fractionLVEF groupsKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreMildly reduced left ventricular ejection fractionBaseline left ventricular ejection fractionReduced left ventricular ejection fractionClinical summary scoreHeart failureNo significant differenceEjection fractionClinical outcomesLVEF spectrumSignificant differenceLeft ventricular ejection fraction dataEnd pointsSpectrum of ejection fractionEffect of torsemideRisk of clinical outcomesVentricular ejection fractionStudy end pointBaseline patient characteristicsClinical end pointsSummary scoreAll-cause mortalityPrevalence of comorbiditiesSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysisDapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction
Vardeny O, Desai A, Jhund P, Fang J, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mc Causland F, Petrie M, Vaduganathan M, McMurray J, Solomon S. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction. JAMA Cardiology 2024, 9: 283-289. PMID: 38265835, PMCID: PMC10809142, DOI: 10.1001/jamacardio.2023.5318.Peer-Reviewed Original ResearchMeSH KeywordsBenzhydryl CompoundsGlucosidesHeart FailureHumansSodium-Glucose Transport ProteinsStroke VolumeVentricular Function, LeftConceptsLeft ventricular ejection fractionMode of deathEjection fractionCause-specific deathHeart failureCardiovascular deathNew York Heart Association class IIGuideline-directed medical therapyStudy case report formsSudden deathVentricular ejection fractionRate of sudden deathAssociated with lower ratesCox regression modelsImproved ejection fractionRandomized clinical trialsReduce cardiovascular mortalityCase report formsEnd-point committeeClinical end point committeePost hoc analysisDapagliflozin EvaluationIV symptomsHFimpEFMedical therapyFactors associated with reporting left ventricular ejection fraction with 3D echocardiography in real‐world practice
Faridi K, Zhu Z, Shah N, Crandall I, McNamara R, Flueckiger P, Bachand K, Lombo B, Hur D, Agarwal V, Reinhardt S, Velazquez E, Sugeng L. Factors associated with reporting left ventricular ejection fraction with 3D echocardiography in real‐world practice. Echocardiography 2024, 41: e15774. PMID: 38329886, DOI: 10.1111/echo.15774.Peer-Reviewed Original ResearchMeSH KeywordsEchocardiography, Three-DimensionalFemaleHumansMaleStroke VolumeVentricular Function, LeftConceptsTransthoracic echocardiogramVentricular ejection fractionOutpatient transthoracic echocardiogramsReal-world practiceEjection fractionLeft ventricular ejection fractionAssess left ventricular ejection fractionInpatient transthoracic echocardiogramsMultivariate logistic regressionLVEFHospitalized patientsMedical CenterSonographersClinical settingLogistic regressionUltrasound machineChemotherapyContrast enhancement agentsPortable studiesNegative associationArtificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction
Wu J, Biswas D, Ryan M, Bernstein B, Rizvi M, Fairhurst N, Kaye G, Baral R, Searle T, Melikian N, Sado D, Lüscher T, Grocott‐Mason R, Carr‐White G, Teo J, Dobson R, Bromage D, McDonagh T, Shah A, O'Gallagher K. Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction. European Journal Of Heart Failure 2024, 26: 302-310. PMID: 38152863, DOI: 10.1002/ejhf.3115.Peer-Reviewed Original ResearchMeSH KeywordsArtificial IntelligenceHeart FailureHumansPrognosisRetrospective StudiesStroke VolumeVentricular Function, LeftConceptsLeft ventricular ejection fractionDiagnosis of HFpEFEuropean Society of CardiologyHeart failureNatural language processingElectronic health recordsEuropean Society of Cardiology criteriaClinical diagnosis of HFEuropean Society of Cardiology diagnostic criteriaDiagnostic criteriaVentricular ejection fractionRetrospective cohort studyDiagnosis of HFSociety of CardiologyClinician-assigned diagnosisConsecutive patientsHFpEF patientsEjection fractionElectronic health record dataAcute cardiovascular eventsExpert clinical reviewNatural language processing methodsNatural language processing pipelineHFpEFCardiovascular events
2023
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
Butt J, Jering K, DE Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Jhund P, Køber L, Kosiborod M, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Langkilde A, Bengtsson O, Petersson M, Sjöstrand M, Wilderäng U, Solomon S, McMurray J. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. Journal Of Cardiac Failure 2023, 30: 436-448. PMID: 38104937, DOI: 10.1016/j.cardfail.2023.08.027.Peer-Reviewed Original ResearchMeSH KeywordsBenzhydryl CompoundsGlucosidesHeart FailureHumansQuality of LifeRandomized Controlled Trials as TopicStroke VolumeVentricular Function, LeftConceptsHistory of sleep apneaPrevalence of sleep apneaEffects of dapagliflozinSleep apneaWorsening HF eventsDAPA-HFAssociated with higher ratesHeart failureClinical outcomesEjection fractionPooled analysisComposite of worsening HFEffects of HF therapiesPrimary outcomeHF eventsDELIVER trialBenefits of dapagliflozinDAPA-HF trialAssociated with outcomePrimary endpointHF therapyHigher ratesHF phenotypesApneaTreatment optionsEfficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
Kondo T, Butt J, Curtain J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure 2023, 16: e010898. PMID: 37886880, DOI: 10.1161/circheartfailure.123.010898.Peer-Reviewed Original ResearchMeSH KeywordsAtrial FibrillationHeart FailureHeart Failure, SystolicHeart RateHumansStroke VolumeVentricular Dysfunction, LeftVentricular Function, LeftConceptsLeft ventricular ejection fractionReduced ejection fractionVentricular ejection fractionPatient-level pooled analysisBenefit of dapagliflozinEjection fractionHeart failureAtrial fibrillationBaseline heart rateSinus rhythmHeart ratePrimary outcomeDAPA-HFCardiovascular deathPooled analysisHR rangeEfficacy of dapagliflozinEffect of dapagliflozinHeart failure phenotypeHigher heart rateCardiovascular eventsHazard ratioHigh riskFailure phenotypePatientsIncidence and Prognostic Implications of Cardiac-Implantable Device-Associated Tricuspid Regurgitation: A Meta-Analysis and Meta-Regression Analysis
Safiriyu I, Mehta A, Adefuye M, Nagraj S, Kharawala A, Hajra A, Shamaki G, Kokkinidis D, Bob-Manuel T. Incidence and Prognostic Implications of Cardiac-Implantable Device-Associated Tricuspid Regurgitation: A Meta-Analysis and Meta-Regression Analysis. The American Journal Of Cardiology 2023, 209: 203-211. PMID: 37863117, DOI: 10.1016/j.amjcard.2023.09.064.Peer-Reviewed Original ResearchMeSH KeywordsAgedDefibrillators, ImplantableFemaleHeart FailureHumansIncidencePrognosisRegression AnalysisRetrospective StudiesStroke VolumeTricuspid Valve InsufficiencyVentricular Function, LeftConceptsCardiac implantable electronic devicesTricuspid regurgitationMeta-regression analysisHF hospitalizationCause mortalityPrognostic implicationsEligible studiesComposite of mortalityHeart failure hospitalizationVentricular ejection fractionElectronic databases MEDLINEMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsRandom-effects modelFinal quantitative analysisWeb of ScienceCardiac implantable devicesImplantable electronic devicesFailure hospitalizationMean followEjection fractionDevice implantationTrue incidenceMean ageOdds ratioDapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
Ostrominski J, Vaduganathan M, Selvaraj S, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation 2023, 148: 1945-1957. PMID: 37830208, DOI: 10.1161/circulationaha.123.065254.Peer-Reviewed Original ResearchMeSH KeywordsBenzhydryl CompoundsHeart FailureHumansHypertensionStroke VolumeVentricular Function, LeftConceptsApparent treatment-resistant hypertensionBaseline blood pressureTreatment-resistant hypertensionVentricular ejection fractionEjection fractionNonresistant hypertensionPrimary outcomeHeart failureBP categoriesHigher left ventricular ejection fractionSystolic baseline blood pressureLeft ventricular ejection fractionRelative treatment benefitSerious adverse eventsKey secondary outcomesRisk of hypotensionWorse kidney functionHigh-risk populationProportion of participantsBaseline BP categoriesGreater absolute reductionCardiometabolic comorbiditiesHypertension groupVascular eventsAdverse eventsMyocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis
Liu D, Wang M, Murthy V, McNamara D, Nguyen T, Philips T, Vyas H, Gao H, Sahni J, Starling R, Cooper L, Skime M, Batzler A, Jenkins G, Barlera S, Pileggi S, Mestroni L, Merlo M, Sinagra G, Pinet F, Krejčí J, Chaloupka A, Miller J, de Groote P, Tschumperlin D, Weinshilboum R, Pereira N. Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis. Circulation Research 2023, 133: 810-825. PMID: 37800334, PMCID: PMC10746262, DOI: 10.1161/circresaha.123.323200.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmCardiomyopathy, DilatedCell Adhesion MoleculesFibrosisGenome-Wide Association StudyHeart FailureHumansStroke VolumeVentricular Function, LeftConceptsGenome-wide association studiesAssociation studiesRecent-onset dilated cardiomyopathyGenome-wide association study signalsLeft ventricular ejection fractionVentricular ejection fractionDilated cardiomyopathyHuman cardiac fibroblastsCardiac fibrosisMyocardial recoveryEjection fractionHeart failureAssociated with improved cardiac functionTranscriptome profilingCDCP1 expressionStandard drug therapyMolecular mechanismsVariant allelesAttenuated cardiac fibrosisHeart failure patientsCellular modelKnockdownDecreased AktStudy signalsCDCP1Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure
Souza A, Rosenthal M, Moura F, Divakaran S, Osborne M, Hainer J, Dorbala S, Blankstein R, Di Carli M, Taqueti V. Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure. JACC Cardiovascular Imaging 2023, 17: 179-191. PMID: 37768241, PMCID: PMC10922555, DOI: 10.1016/j.jcmg.2023.07.014.Peer-Reviewed Original ResearchMeSH KeywordsCoronary Artery DiseaseFemaleHeart FailureHumansMaleMiddle AgedObesityPredictive Value of TestsRisk FactorsStroke VolumeVentricular Function, LeftConceptsCoronary microvascular dysfunctionVisceral adipose tissueAssociated with coronary microvascular dysfunctionCoronary flow reserveBody mass indexLow coronary flow reserveSubcutaneous adipose tissueCoronary artery diseaseAdverse eventsPositron emission tomographyObese patientsMicrovascular dysfunctionVisceral adipose tissue cross-sectional areaCardiovascular eventsHeart failurePreserved left ventricular ejection fractionAdverse outcomesSkeletal muscleArtery diseaseFlow-limiting coronary artery diseaseBody compositionAssociated with body compositionEvaluation of coronary artery diseaseStress positron emission tomographyEmission tomographyHeart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments.
Sen S. Heart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments. The American Journal Of Managed Care 2023, 29: s180-s186. PMID: 37677742, DOI: 10.37765/ajmc.2023.89415.Peer-Reviewed Original ResearchMeSH KeywordsAdultCognitionFinancial StressHeart FailureHumansStroke VolumeVentricular Function, LeftConceptsGuideline-directed medical therapyReduced ejection fractionHeart failureEjection fractionEconomic burdenManagement of HFrEFPresence of comorbiditiesEmergency department visitsVentricular ejection fractionDisease-modifying therapiesPoor treatment adherenceHealth care systemDepartment visitsMedical therapyPatient factorsComorbid conditionsMedication costsTreatment adherenceOptimal treatmentOutpatient carePreventable hospitalizationsIndividual patientsHigh riskTarget dosesMedical costsHeart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER
Butt J, Lu H, Kondo T, Bachus E, de Boer R, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Vaduganathan M, Solomon S, McMurray J. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. European Journal Of Heart Failure 2023, 25: 2078-2090. PMID: 37634087, DOI: 10.1002/ejhf.3000.Peer-Reviewed Original ResearchMeSH KeywordsBenzhydryl CompoundsHeart FailureHumansPulmonary Disease, Chronic ObstructiveStroke VolumeVentricular Function, LeftConceptsChronic obstructive pulmonary diseaseModerate chronic obstructive pulmonary diseaseCOPD statusSafety of dapagliflozinObstructive pulmonary diseaseHeart failurePulmonary diseasePrimary outcomeEjection fractionWorse outcomesKansas City Cardiomyopathy Questionnaire scoreBenefit of dapagliflozinPre-specified analysisSevere pulmonary diseaseCardiovascular deathCause hospitalizationPrimary endpointTreatment discontinuationAdverse eventsClinical eventsQuestionnaire scoresPlaceboDapagliflozinPatientsKnown historyOutpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
Chatur S, Vaduganathan M, Claggett B, Cunningham J, Docherty K, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation 2023, 148: 1735-1745. PMID: 37632455, PMCID: PMC10664793, DOI: 10.1161/circulationaha.123.066506.Peer-Reviewed Original ResearchMeSH KeywordsBenzhydryl CompoundsDiureticsHeart FailureHeart Failure, DiastolicHumansOutpatientsStroke VolumeVentricular Function, LeftConceptsUrgent HF visitsComposite end pointHeart failureHF hospitalizationHF visitsHF eventsFirst presentationCardiovascular deathEnd pointEjection fractionSubsequent mortalitySubsequent deathEjection fraction heart failurePrimary end pointCardiovascular causesClinical decompensationPrespecified analysisAmbulatory carePatientsClinical relevanceSentinel eventsHospitalizationDapagliflozinDeathVisits
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply